Legacy AI grade · Sources dated 2026-06-09. Not expert reviewed. Coverage is limited to the listed sources. About the new summary workflow
Prebiotics for Glucose Control
Verdict: Published with Warning
Across 4 PubMed studies, the evidence for Prebiotics in Glucose Control grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
Prebiotics show modest glycemic effects in some meta-analyses, but adjudication correctly downgraded B→C for surrogate-only endpoints. PMID 31805963 and 30607329 are genuine prebiotic/synbiotic glycemic MAs.
PMID 35987483 covers probiotics+synbiotics (broader than prebiotics alone) and PMID 38309832 is a CVD-risk-factor MA, not glucose control. evidence_level claimed '4 meta-analyses'.
Tier C reflects small, surrogate-heavy HbA1c/fasting-glucose changes without hard outcomes. Do not treat prebiotic evidence as diabetes treatment.
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.65
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
80%
Broadly consistent
Evidence level
E3
PMID 35987483 is probiotics+synbiotics; PMID 38309832 is CVD-risk MA not glucose control
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.645
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (4)L2 · primary research & systematic reviews
Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials
Finding: Inulin-type fructans significantly reduced FBG (WMD -0.60 mmol/L, 95% CI -0.71 to -0.48; high-quality GRADE) and HbA1c (WMD -0.58%, 95% CI -0.83 to -0.32, P<0.00001; high-quality GRADE), with effect concentrated in prediabetes/T2DM at >=10 g/day for >=6 weeks; insulin and HOMA-IR effects were low-quality.
View on PubMed Effects of Prebiotic and Synbiotic Supplementation on Glycaemia and Lipid Profile in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Finding: Pooled prebiotic/synbiotic supplementation lowered FBG (WMD -11.74 mg/dL, 95% CI -23.04 to -0.44, P<0.05) and HbA1c (WMD -0.49%, 95% CI -0.77 to -0.21, P<0.05); in the prebiotic-only subgroup FBG fell -12.40 mg/dL (95% CI -15.86 to -8.94, P<0.0001) and HbA1c -0.47% (95% CI -0.80 to -0.13, P<0.0001), while the synbiotic-glucose subgroup was non-significant.
View on PubMed The effects of inulin-type fructans on cardiovascular disease risk factors: systematic review and meta-analysis of randomized controlled trials
Finding: Inulin-type fructans produced only small reductions in LDL-C (MD -0.14 mmol/L, 95% CI -0.24 to -0.05; very low certainty), triglycerides (MD -0.06 mmol/L, 95% CI -0.12 to -0.01; low certainty) and body weight (MD -0.97 kg, 95% CI -1.28 to -0.66; low certainty), with little to no significant effect on other CVD risk factors, indicating the downstream cardiometabolic benefit is modest and low-certainty.
View on PubMed Probiotics and synbiotics supplementation improve glycemic control parameters in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials
Finding: Probiotics/synbiotics significantly reduced FPG (WMD -11.18 mg/dL, 95% CI -13.60 to -8.75, P<0.001), HbA1c (WMD -0.35%, 95% CI -0.44 to -0.26, P<0.001), HOMA-IR (WMD -0.87, 95% CI -1.09 to -0.65, P<0.001) and fasting insulin (WMD -1.23 uIU/mL, 95% CI -1.76 to -0.71, P<0.001); relevant only as adjacent gut-microbiome evidence since the prebiotic component is bundled with live bacteria.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
the FDA intends to exercise enforcement discretion ... for the use of inulin (and inulin-type fructans) ... as a dietary fiber on the Nutrition and Supplement Facts labels source↗
L4b EU EFSA
Supportive
L4c UK NHS
Neutral
Government guidelines say our dietary fibre intake should increase to 30g a day, as part of a healthy balanced diet. source↗
L4d TW TFDA / 衛福部
Neutral
目前健康食品可以宣稱的保健功效項目共有13項，包括調節血脂、胃腸功能改善、護肝、免疫調節、骨質保健、不易形成體脂肪、抗疲勞、輔助調整過敏體質、調節血糖、延緩衰老、牙齒保健、促進鐵吸收、輔助調節血壓。 source↗
L4e WHO
Neutral
WHO recommends an intake of naturally occurring dietary fibre of at least 25 g per day for adults. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Supportive
Research indicates that high prebiotic consumption may enhance our immune system, help regulate blood sugar levels, reduce the risk of colorectal cancer and increase calcium absorption. The most common prebiotics are inulin, oligosaccharides and pectin, which are found in fibrous foods. source↗
L5c Cleveland Clinic
Supportive
Fiber helps keep us full and stabilizes our blood sugars. This can prevent us from over-eating and help us make better food choices. Some studies have shown that inulin can help repair the gut microbiome when it's been damaged by health conditions like Type 2 diabetes, gastrointestinal diseases, obesity and prolonged appetite suppression. source↗
L5d Harvard Health
Supportive
research has found a link between higher prebiotic intake and improved intestinal absorption of dietary calcium, better blood sugar control, a well-functioning immune system, a reduce risk of colorectal cancer. source↗